"I have been in sales management in pharma and actual goods leaving the depts /factory was considered as sales."
Not wanting to highlight the same thing - but many a company has run into trouble booking revenue when product leaves depts/factories. This is not how it is done unless you want to see the CFO in jail. Of course MYX actually got caught with this and had to adjust for Derm!
We'd hope MYX with Nextstellis is different - we are just talking about "cycles". Regardless of which way they are reported - the growth rates are similar and unfortunately the last few months have been flat. Reporting type is semantics as the market is wanting revenue growth for a product that has cost Hundreds and Hundreds and Hundreds of $millions.
GLTA.
"I have been in sales management in pharma and actual goods...
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.93 |
Change
0.030(0.61%) |
Mkt cap ! $419.4M | |||
| Open | High | Low | Value | Volume |
| $4.92 | $4.94 | $4.81 | $766.3K | 156.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 110 | $4.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.94 | 993 | 1 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.91 |
Change
0.030 ( 0.29 %) |
||||
| Open | High | Low | Volume | ||
| $4.92 | $4.94 | $4.82 | 85313 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| MYX (ASX) Chart |